ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated by Analysts at Guggenheim
Guggenheim began coverage on shares of ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $45.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 100.18% from the stock’s previous close. Separately, HC […]
Guggenheim began coverage on shares of ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $45.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 100.18% from the stock’s previous close. Separately, HC […]
